Identification
Name19-norandrostenedione
Accession NumberDB01434
TypeSmall Molecule
GroupsExperimental, Illicit
Description

19-Norandrostenedione refers to two steroid isomers that were once marketed as dietary supplements and mainly used by body builders. After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency.

In the body 19-norandrostenedione is rapidly metabolized into nandrolone, also known as nortestosterone.

Structure
Thumb
Synonyms
4-estrene-3,17-dione
delta4-Estrene-3,17-dione
NOR
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
19-N-AndroNot Available
BolandioneNot Available
Proven Pure 19-NorandrostenedioneNot Available
Brand mixturesNot Available
Categories
UNIIU90987PVU5
CAS number734-32-7
WeightAverage: 272.382
Monoisotopic: 272.177630012
Chemical FormulaC18H24O2
InChI KeyJRIZOGLBRPZBLQ-QXUSFIETSA-N
InChI
InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-16H,2-9H2,1H3/t13-,14+,15+,16-,18-/m0/s1
IUPAC Name
(1S,2R,10R,11S,15S)-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-ene-5,14-dione
SMILES
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
Pharmacology
Indication

The claim that supplemental 19-norandrostenedione has anabolic effects is unsubstantiated.

Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

19-Norandrostenedione may be metabolized to 19-nortestosterone in both men and women. 19-Norandrostenedione, also known as nandrolone, is the basic substance of some very popular injectable anabolic steroids, however 19-norandrostenedione is not metabolized to testosterone. Whether or not increases in 19-nortestosterone levels would be sustained long enough by taking 19-norandrostenedione to show an increase in nitrogen retention and muscle strength and mass is unknown.

19-Norandrostenedione has also been shown to bind to androgen receptors with high selectivity. Transactivation of androgen receptor dependent reporter gene expression was 10 times lower than that produced by dihydrotestosterone. [1]

Related Articles
Absorption

Absorption appears variable, but some absorption does occur.

Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Specific metabolites of 19-nor-5-androstene-3, 17-dione are 19-nordehydroandrosterone and 19-nordehydroepiandrosterone.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with 19-norandrostenedione.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with 19-norandrostenedione.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with 19-norandrostenedione.Approved
Aldesleukin19-norandrostenedione may decrease the antineoplastic activities of Aldesleukin.Approved
Aluminum hydroxideThe bioavailability of 19-norandrostenedione can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with 19-norandrostenedione.Approved
AmiodaroneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin B19-norandrostenedione may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with 19-norandrostenedione.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with 19-norandrostenedione.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with 19-norandrostenedione.Approved, Investigational
AprepitantThe serum concentration of 19-norandrostenedione can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of 19-norandrostenedione.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with 19-norandrostenedione.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with 19-norandrostenedione.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with 19-norandrostenedione.Approved, Investigational
BazedoxifeneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Bazedoxifene.Approved, Investigational
Bendroflumethiazide19-norandrostenedione may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with 19-norandrostenedione.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with 19-norandrostenedione.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with 19-norandrostenedione.Investigational
Bismuth SubcitrateThe bioavailability of 19-norandrostenedione can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Boceprevir.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with 19-norandrostenedione.Approved
Bumetanide19-norandrostenedione may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with 19-norandrostenedione.Approved, Nutraceutical
Calcium carbonateThe bioavailability of 19-norandrostenedione can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with 19-norandrostenedione.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with 19-norandrostenedione.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with 19-norandrostenedione.Approved, Investigational
Ceritinib19-norandrostenedione may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with 19-norandrostenedione.Approved, Vet Approved
Chlorothiazide19-norandrostenedione may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Chlorotrianisene.Withdrawn
Chlorthalidone19-norandrostenedione may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of 19-norandrostenedione can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with 19-norandrostenedione.Approved
CobicistatThe serum concentration of 19-norandrostenedione can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensThe serum concentration of 19-norandrostenedione can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with 19-norandrostenedione.Approved
DarunavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Demecarium.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with 19-norandrostenedione.Approved, Vet Approved
DienestrolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with 19-norandrostenedione.Approved
Dihydrotestosterone19-norandrostenedione may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DonepezilThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with 19-norandrostenedione.Approved
EchothiophateThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with 19-norandrostenedione.Approved
EstradiolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Estrone.Approved
Etacrynic acid19-norandrostenedione may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with 19-norandrostenedione.Approved, Investigational
Ethinyl EstradiolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with 19-norandrostenedione.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with 19-norandrostenedione.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with 19-norandrostenedione.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with 19-norandrostenedione.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with 19-norandrostenedione.Approved
FleroxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with 19-norandrostenedione.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Flumequine.Withdrawn
Fluoxymesterone19-norandrostenedione may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with 19-norandrostenedione.Approved, Investigational
FosaprepitantThe serum concentration of 19-norandrostenedione can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Fosphenytoin.Approved
Furosemide19-norandrostenedione may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gallamine Triethiodide.Approved
GatifloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of 19-norandrostenedione can be increased when it is combined with Genistein.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with 19-norandrostenedione.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Hexestrol.Withdrawn
Huperzine AThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with 19-norandrostenedione.Approved, Investigational
Hydrochlorothiazide19-norandrostenedione may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
Hydroflumethiazide19-norandrostenedione may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with 19-norandrostenedione.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with 19-norandrostenedione.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with 19-norandrostenedione.Approved
IdelalisibThe serum concentration of 19-norandrostenedione can be increased when it is combined with Idelalisib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of 19-norandrostenedione.Approved
Indapamide19-norandrostenedione may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with 19-norandrostenedione.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with 19-norandrostenedione.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with INGN 225.Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with 19-norandrostenedione.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with 19-norandrostenedione.Withdrawn
ItraconazoleThe serum concentration of 19-norandrostenedione can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with 19-norandrostenedione.Experimental
KetoconazoleThe serum concentration of 19-norandrostenedione can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with 19-norandrostenedione.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with 19-norandrostenedione.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with 19-norandrostenedione.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Levofloxacin.Approved, Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Lomefloxacin.Approved
LopinavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with 19-norandrostenedione.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with 19-norandrostenedione.Approved
LumacaftorThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with 19-norandrostenedione.Approved, Investigational
MagaldrateThe bioavailability of 19-norandrostenedione can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium carbonate.Approved
Magnesium HydroxideThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 19-norandrostenedione.Approved
Magnesium TrisilicateThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with 19-norandrostenedione.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 19-norandrostenedione.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with 19-norandrostenedione.Approved
MefloquineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with 19-norandrostenedione.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with 19-norandrostenedione.Approved
MestranolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with 19-norandrostenedione.Withdrawn
MethallenestrilThe serum concentration of 19-norandrostenedione can be increased when it is combined with Methallenestril.Experimental
Methyclothiazide19-norandrostenedione may increase the hypokalemic activities of Methyclothiazide.Approved
Methyltestosterone19-norandrostenedione may increase the fluid retaining activities of Methyltestosterone.Approved
Metolazone19-norandrostenedione may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of 19-norandrostenedione can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Minaprine.Approved
MitotaneThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of 19-norandrostenedione.Approved
MoxifloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with 19-norandrostenedione.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 19-norandrostenedione.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with 19-norandrostenedione.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with 19-norandrostenedione.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with 19-norandrostenedione.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with 19-norandrostenedione.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with 19-norandrostenedione.Investigational
NefazodoneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with 19-norandrostenedione.Approved
NevirapineThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with 19-norandrostenedione.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with 19-norandrostenedione.Approved, Withdrawn
NorfloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with 19-norandrostenedione.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with 19-norandrostenedione.Approved
Oxandrolone19-norandrostenedione may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with 19-norandrostenedione.Approved
Oxymetholone19-norandrostenedione may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 19-norandrostenedione.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with 19-norandrostenedione.Approved
PefloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with 19-norandrostenedione.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with 19-norandrostenedione.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with 19-norandrostenedione.Approved, Investigational
PhenytoinThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with 19-norandrostenedione.Approved, Investigational
Piretanide19-norandrostenedione may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with 19-norandrostenedione.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with 19-norandrostenedione.Approved, Investigational
Polythiazide19-norandrostenedione may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of 19-norandrostenedione can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Primidone.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with 19-norandrostenedione.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with 19-norandrostenedione.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of 19-norandrostenedione can be increased when it is combined with Quinestrol.Approved
Quinethazone19-norandrostenedione may increase the hypokalemic activities of Quinethazone.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of 19-norandrostenedione.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with 19-norandrostenedione.Experimental, Investigational
RifabutinThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with CDX-110.Investigational
RitonavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with 19-norandrostenedione.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rosoxacin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with 19-norandrostenedione.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with 19-norandrostenedione.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with 19-norandrostenedione.Approved
SaquinavirThe serum concentration of 19-norandrostenedione can be increased when it is combined with Saquinavir.Approved, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with 19-norandrostenedione.Investigational
St. John's WortThe serum concentration of 19-norandrostenedione can be decreased when it is combined with St. John's Wort.Nutraceutical
Stanozolol19-norandrostenedione may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with 19-norandrostenedione.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with 19-norandrostenedione.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with 19-norandrostenedione.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of 19-norandrostenedione can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of 19-norandrostenedione can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with 19-norandrostenedione.Withdrawn
TelithromycinThe serum concentration of 19-norandrostenedione can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with 19-norandrostenedione.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with 19-norandrostenedione.Approved
Testosterone19-norandrostenedione may increase the fluid retaining activities of Testosterone.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with 19-norandrostenedione.Approved
TiboloneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Tibolone.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with 19-norandrostenedione.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with 19-norandrostenedione.Approved
Torasemide19-norandrostenedione may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with 19-norandrostenedione.Approved, Investigational
Trichlormethiazide19-norandrostenedione may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with 19-norandrostenedione.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with 19-norandrostenedione.Investigational, Withdrawn
VoriconazoleThe serum concentration of 19-norandrostenedione can be increased when it is combined with Voriconazole.Approved, Investigational
Warfarin19-norandrostenedione may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with 19-norandrostenedione.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with 19-norandrostenedione.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with 19-norandrostenedione.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Diel P, Friedel A, Geyer H, Kamber M, Laudenbach-Leschowsky U, Schanzer W, Schleipen B, Thevis M, Vollmer G, Zierau O: The prohormone 19-norandrostenedione displays selective androgen receptor modulator (SARM) like properties after subcutaneous administration. Toxicol Lett. 2008 Apr 1;177(3):198-204. doi: 10.1016/j.toxlet.2008.01.014. Epub 2008 Feb 2. [PubMed:18325697 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0454 mg/mLALOGPS
logP2.53ALOGPS
logP3.63ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)19.19ChemAxon
pKa (Strongest Basic)-4.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.14 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity79.13 m3·mol-1ChemAxon
Polarizability31.54 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9723
Caco-2 permeable+0.7785
P-glycoprotein substrateSubstrate0.5551
P-glycoprotein inhibitor IInhibitor0.8097
P-glycoprotein inhibitor IINon-inhibitor0.6972
Renal organic cation transporterNon-inhibitor0.638
CYP450 2C9 substrateNon-substrate0.827
CYP450 2D6 substrateNon-substrate0.9064
CYP450 3A4 substrateSubstrate0.6816
CYP450 1A2 substrateNon-inhibitor0.8259
CYP450 2C9 inhibitorNon-inhibitor0.9269
CYP450 2D6 inhibitorNon-inhibitor0.94
CYP450 2C19 inhibitorNon-inhibitor0.7094
CYP450 3A4 inhibitorNon-inhibitor0.8652
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7931
Ames testNon AMES toxic0.9189
CarcinogenicityNon-carcinogens0.9403
BiodegradationNot ready biodegradable0.9401
Rat acute toxicity1.6104 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7011
hERG inhibition (predictor II)Non-inhibitor0.7574
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
KingdomChemical entities
Super ClassOrganic compounds
ClassLipids and lipid-like molecules
Sub ClassSteroids and steroid derivatives
Direct ParentEstrogens and derivatives
Alternative Parents3-oxo delta-4-steroids / 17-oxosteroids / Delta-4-steroids / Cyclohexenones / Organic oxides / Hydrocarbon derivatives
SubstituentsEstrogen-skeleton / Oxosteroid / 17-oxosteroid / 3-oxosteroid / 3-oxo-delta-4-steroid / Delta-4-steroid / Cyclohexenone / Cyclic ketone / Ketone / Organic oxygen compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors3-oxo steroid (CHEBI:34187 )
Drug created on July 24, 2007 14:36 / Updated on June 11, 2017 20:32